Press coverage about Five Prime Therapeutics (NASDAQ:FPRX) has trended somewhat positive on Thursday, according to Accern. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Five Prime Therapeutics earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.0512561124838 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Five Prime Therapeutics Sees Hammer Chart Pattern: Time to Buy? (finance.yahoo.com)
- Brokerages Expect Five Prime Therapeutics Inc (FPRX) to Post -$1.38 Earnings Per Share (americanbankingnews.com)
- Five Prime Therapeutics (FPRX) Presents At Goldman Sachs 39th Annual Global Healthcare Conference – Slideshow (seekingalpha.com)
- Benzinga’s Top Upgrades, Downgrades For June 15, 2018 (benzinga.com)
- Year-to-date (YTD) under Review Liberty TripAdvisor Holdings, Inc. (NASDAQ:LTRPA), ACCO Brands Corporation … (stocksnewspoint.com)
FPRX traded down $0.55 during trading hours on Thursday, reaching $17.13. 233,059 shares of the stock traded hands, compared to its average volume of 499,381. The firm has a market cap of $609.47 million, a price-to-earnings ratio of -3.18 and a beta of 3.41. Five Prime Therapeutics has a fifty-two week low of $15.66 and a fifty-two week high of $48.87.
Several equities analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, March 2nd. Wedbush began coverage on shares of Five Prime Therapeutics in a research note on Thursday, May 17th. They set a “neutral” rating and a $17.00 price target on the stock. BidaskClub raised shares of Five Prime Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 19th. BMO Capital Markets cut their price target on shares of Five Prime Therapeutics from $75.00 to $60.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 28th. Finally, Nomura cut their price target on shares of Five Prime Therapeutics from $94.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday, February 28th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $33.00.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.